The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.

<h4>Background</h4>The introduction of specific BCR-ABL inhibitors in chronic myelogenous leukemia therapy has entirely mutated the prognosis of this hematologic cancer from being a fatal disorder to becoming a chronic disease. Due to the probable long lasting treatment with tyrosine-kin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Adriana Borriello, Ilaria Caldarelli, Maria Assunta Basile, Debora Bencivenga, Annunziata Tramontano, Silverio Perrotta, Fulvio Della Ragione, Adriana Oliva
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2011
Materias:
R
Q
Acceso en línea:https://doaj.org/article/16c48b6ed8714db89955d42804853f88
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!